Effects of Solriamfetol on Cognitive Function in Participants With Cognitive Impairment Associated With Excessive Daytime Sleepiness in Obstructive Sleep Apnea: Results of the SHARP Study,
Poster presented at AAN 2023, the 75th Annual Meeting of American Academy of Neurology [AAN]
Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany,
Sleep Medicine, March 2023
Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea with a History of Depression,
Journal of Psychiatric Research, November 2022
Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion,
poster presented at SLEEP 2022, the 36th Annnual Meeting of the Associated Professional Sleep Societies [APSS]
Incidence and Duration of Common Early-Onset Adverse Events in Randomized Controlled Trials of Solriamfetol for Treatment of Excessive Daytime Sleepiness in Obstructive Sleep Apnea and Narcolepsy,
Journal of Clinical Sleep Medicine, January 2022
Indirect Treatment Comparison of Solriamfetol, Modafinil, and Armodafinil for Excessive Daytime Sleepiness in Obstructive Sleep Apnea,
Journal of Clinical Sleep Medicine, December 2021
Long-Term Effects of Solriamfetol on Quality of Life and Work Productivity in Participants with Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea,
Journal of Clinical Sleep Medicine, October 2021
Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment,
CHEST, July 2021
Effects of Solriamfetol In A Long-Term Trial of Patients With Obstructive Sleep Apnea Who Are Adherent or Nonadherent With To Airway Therapy,
Journal of Clinical Sleep Medicine, April 2021
Clinically Relevant Effects of Solriamfetol on Excessive Daytime Sleepiness: A Post Hoc Analysis of the Magnitude of Change in Clinical Trials in Adults with Narcolepsy or Obstructive Sleep Apnea,
Journal of Clinical Sleep Medicine, April 2021
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial,
Annals of the American Thoracic Society, August 2020
Understanding the Burden of Illness of Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea: A Qualitative Study,
Health and Quality of Life Outcomes, May 2020
Measures of Functional Outcomes, Work Productivity, and Quality of Life from a Randomized, Phase 3 Study of Solriamfetol in Participants with Narcolepsy,
Journal of Clinical Sleep Medicine, March 2020
Long-Term Study of the Safety and Maintenance of Efficacy of Solriamfetol (JZP-110) in the Treatment of Excessive Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea,
SLEEP, February 2020
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial,
American Journal of Respiratory and Critical Care Medicine, June 2019
A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy,
Annals of Neurology, March 2019
Comorbidities, Health-Related Quality of Life, and Work Productivity Among People With Obstructive Sleep Apnea With Excessive Sleepiness: Findings From the 2016 US National Health and Wellness Survey,
Journal of Clinical Sleep Medicine, February 2019
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study,
CHEST, February 2019
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor,
Journal of Pharmacology and Experimental Therapeutics, August 2018
